In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dynavax Technologies Corp.

www.dynavax.com

Latest From Dynavax Technologies Corp.

Finance Watch: A Rough Week To End A Bad Month For Biotech Stocks

Public Company Edition: The prior day's after-hours bad news sent biotech stocks lower on 9 August, and IPOs are taking a breather with the NBI down 2.1% over the past month. However, already public companies are raising cash, including Allakos and Ironwood at $350m each.

Financing Business Strategies

Dosing Woes For VBI Vaccines As Share Price Plummets On Hep B Study Results

Despite positive results in the latest Phase III PROTECT study of its hepatitis B vaccine, VBI Vaccines failed to show non-inferiority at two doses, leaving it trailing behind competitor Dynavax and its established two-dose product.

Infectious Diseases Vaccines

Finance Watch: Three New Biopharma IPOs In The US With Eight More Entering The Queue

Public Company Edition: IPO performance has been mixed in 2019, but May has been the busiest month this year. Also, Insmed leads recent follow-on offerings and Dynavax restructures.

Financing Business Strategies

Finance Watch: Genfit Launches IPO To Expand US Presence Ahead Of Phase III NASH Results

Public Company Edition: COO Dean Hum talked to Scrip about Genfit's IPO strategy – which wasn't just about raising money – as it anticipates Phase III elafibranor data later this year. Also, Precision BioSciences launches its IPO, while Myokardia, Dermira and Tricida lead new public company financings.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Infectious & Viral Diseases
  • Inflammation
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Dynavax Technologies Corp.
  • Senior Management
  • Eddie Gray, CEO
    Michael S Ostrach, SVP, CFO & CBO
    Robert L Coffman, PhD, SVP, CSO
    Robert Janssen, MD, VP, Clinical Dev. & CMO
  • Contact Info
  • Dynavax Technologies Corp.
    Phone: (510) 848-5100
    2929 Seventh St.
    Ste. 100
    Berkeley, CA 94710
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register